Table 2 Validation of potential biomarkers for cholestasis in PCLS
A | B | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug | CsA | CsA | CsA | CsA | CsA | MW test | Drug | CPZ | CPZ | CPZ | CPZ | CPZ | MW test |
Gene | FC1 | FC2 | FC3 | FC4 | FC5 | Gene | FC1 | FC2 | FC3 | FC4 | FC5 | ||
ABCG5 | −3.5 | −1.8 | −1.0 | −1.3 | −1.2 | NS | ABCG5 | −4.2 | −2.9 | −6.7 | −3.8 | 1.0 | * |
ABCG8 | −4.9 | −3.9 | −1.2 | −2.0 | −1.2 | * | ABCG8 | −2.9 | −2.1 | −5.4 | −4.5 | −1.1 | * |
BAAT | −5.2 | −4.2 | −1.6 | −2.2 | −1.7 | * | BAAT | −2.3 | −3.3 | −8.5 | −6.4 | 1.4 | * |
KLF15 | −1.2 | −1.7 | −2.0 | −1.4 | −1.3 | * | KLF15 | −2.0 | −1.8 | −3.2 | −1.8 | 1.6 | * |
C | D | ||||||||||||
Drug | A | A | A | A | A | MW test | Drug | VA | VA | VA | VA | VA | MW test |
Gene | FC1 | FC2 | FC3 | FC4 | FC5 | Gene | FC1 | FC2 | FC3 | FC4 | FC5 | ||
ABCG5 | 1.2 | −1.6 | 1.2 | 1.1 | −1.3 | NS | ABCG5 | 2.0 | −1.7 | −1.1 | 1.4 | 1.6 | NS |
ABCG8 | 2.0 | −1.6 | 1.1 | 1.1 | −1.1 | NS | ABCG8 | 2.2 | −1.5 | −1.3 | 1.4 | 1.9 | NS |
BAAT | 1.8 | −2.2 | 1.1 | −1.0 | −1.7 | NS | BAAT | 1.3 | 1.0 | −2.0 | 1.4 | 2.5 | NS |
KLF15 | 2.6 | −1.8 | −1.5 | −1.4 | −1.3 | NS | KLF15 | 1.0 | −1.9 | −1.7 | −1.1 | 1.1 | NS |
E | F | ||||||||||||
Drug | ISND | ISND | ISND | ISND | ISND | MW test | Drug | PQ | PQ | PQ | PQ | PQ | MW test |
Gene | FC1 | FC2 | FC3 | FC4 | FC5 | Gene | FC1 | FC2 | FC3 | FC4 | FC5 | ||
ABCG5 | 2.0 | 3.0 | 1.1 | 2.0 | 2.0 | * | ABCG5 | 1.1 | 1.1 | 1.7 | −1.3 | −1.6 | NS |
ABCG8 | 2.1 | 2.8 | 1.0 | 2.3 | 1.9 | NS | ABCG8 | 1.0 | −1.2 | 1.8 | −1.3 | −1.4 | NS |
BAAT | 1.8 | 1.7 | 1.1 | −1.3 | 1.3 | NS | BAAT | −1.2 | −1.0 | 1.7 | 1.1 | −1.4 | NS |
KLF15 | 1.2 | 2.4 | 1.0 | 1.1 | 1.2 | NS | KLF15 | 1.3 | −1.0 | 1.3 | 1.1 | −1.2 | NS |